期刊文献+

ADP受体P2Y及其拮抗剂在心血管疾病中的作用及研究进展 被引量:2

The research progress of P2Y receptors and its antagonists in cardiovascular diseases
下载PDF
导出
摘要 血小板上的ADP受体主要分为P2X和P2Y两大类,其中P2Y受体的激活与心血管疾病的发生和发展密切相关,其在调节血小板活化聚集、血管炎症、血栓形成等方面具有重要的作用,是ADP受体阻断药作用的靶点,该类药物也是抗血小板药物研发的热点。本文对P2Y受体在心血管疾病发生、发展过程中的作用进行综述,以期为P2Y受体拮抗剂在治疗心血管疾病中的应用提供新的思路和参考。 ADP receptors on platelets are mainly divided into two categories:P2X and P2Y.The activation of P2Y receptor is closely related to the occurrence and development of cardiovascular diseases.It plays an important role in regulating platelet activation and aggregation,vascular inflammation,thrombosis and so on.It is the target of ADP receptor blockers.This kind of drugs is also a hot spot in the research and development of antiplatelet drugs.This article reviews the role of P2Y receptor in the occurrence and development of cardiovascular diseases,in order to provide new ideas and reference for the application of P2Y receptor antagonists in the treatment of cardiovascular diseases.
作者 贾敏 李毅 郭琦琦 翁桓泽 陈玉龙 JIA Min;LI Yi;GUO Qi-qi;WENG Huan-ze;CHEN Yu-long(Institute of Basic and Translational Medicine, Xi’an Medical College, Xi’an 710021, China)
出处 《中国药理学通报》 CAS CSCD 北大核心 2021年第12期1629-1634,共6页 Chinese Pharmacological Bulletin
基金 陕西省科技创新基地-科技资源开放共享平台项目(No 2019PT-26) 西安医学院博士启动基金资助(No 2020DOC23)。
关键词 P2Y受体 心血管疾病 血小板 P2Y_(12)受体拮抗剂 P2Y receptors cardiovascular disease platelets P2Y_(12)receptor antagonist
  • 相关文献

参考文献7

二级参考文献46

  • 1Mega J L,Close S L,Wiviott S D,et al.Cytochrome p450 polymorphisms and response to clopidogrel[J].N Engl J Med,2009,360(21):354-62.
  • 2Angiolillo D J.Variability in responsiveness to oral antiplatelet therapy[J].Am J Cardiol,2009,103(3 Suppl):27-43.
  • 3Halushka M K,Walker L P,Halushka P V.Genetic variation in cyclooxygenase 1:effects on response to aspirin[J].Clin Pharmacol Ther,2003,73(1):122-30.
  • 4Gurbel P A,Bliden K P,DiChiara J,et al.Evaluation of dose-related effects of aspirin on platelet function:results from the aspirin induced platelet effect(ASPECT)study[J].Circulation,2007,115(25):3156-64.
  • 5Maree A O,Curtin R J,Chubb A,et al.Cyclooxygenase-1 haplotype modulates platelet response to aspirin[J].J Thromb Haemost,2005,3(10):2340-5.
  • 6Gonza′lez-Conejero R,Rivera J,Corral J,et al.Biological assessment of aspirin efficacy on healthy individuals:heterogeneous response or aspirin failure[J]?Stroke,2005,36(2):276-80.
  • 7Papafili A,Hill M R,Brull D J,et al.Common promoter variant in cyclooxygenase-2 represses gene expression:evidence of role in acute-phase inflammatory response[J].Arterioscler Thromb Vasc Biol,2002,22(10):1631-6.
  • 8Angiolillo D J,Ferna′ndez-Ortiz A,Bernardo E,et al.Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel[J].Arterioscler Thromb Vasc Biol,2006,26(8):1895-900.
  • 9Lau W C,Gurbel P A,Watkins P B,et al.Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance[J].Circulation,2004,109(2):166-71.
  • 10Suh J W,Koo B K,Zhang S Y,et al.Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel[J].CMAJ,2006,174(12):1715-22.

共引文献44

同被引文献22

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部